These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

705 related articles for article (PubMed ID: 11580226)

  • 1. Dendritic cell vaccination induces cross-reactive cytotoxic T lymphocytes specific for wild-type and natural variant human immunodeficiency virus type 1 epitopes in HLA-A*0201/Kb transgenic mice.
    Abdel-Motal UM; Friedline R; Poligone B; Pogue-Caley RR; Frelinger JA; Tisch R
    Clin Immunol; 2001 Oct; 101(1):51-8. PubMed ID: 11580226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of HLA-A*3101-restricted cytotoxic T-lymphocyte response to human immunodeficiency virus type 1 (HIV-1) in patients with chronic HIV-1 infection.
    Borghan MA; Oka S; Takiguchi M
    Tissue Antigens; 2005 Oct; 66(4):305-13. PubMed ID: 16185326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization.
    Sandberg JK; Leandersson AC; Devito C; Kohleisen B; Erfle V; Achour A; Levi M; Schwartz S; Kärre K; Wahren B; Hinkula J
    Virology; 2000 Jul; 273(1):112-9. PubMed ID: 10891413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary proliferative and cytotoxic T-cell responses to HIV induced in vitro by human dendritic cells.
    Macatonia SE; Patterson S; Knight SC
    Immunology; 1991 Nov; 74(3):399-406. PubMed ID: 1769689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-reactive cytotoxic T lymphocytes induced by V3 loop synthetic peptides from different strains of human immunodeficiency virus type 1.
    Casement KS; Nehete PN; Arlinghaus RB; Sastry KJ
    Virology; 1995 Aug; 211(1):261-7. PubMed ID: 7645219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART).
    Gray CM; Lawrence J; Schapiro JM; Altman JD; Winters MA; Crompton M; Loi M; Kundu SK; Davis MM; Merigan TC
    J Immunol; 1999 Feb; 162(3):1780-8. PubMed ID: 9973442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence of presentation of multiple HIV-1 cytotoxic T lymphocyte epitopes by HLA-B*3501 molecules that are associated with the accelerated progression of AIDS.
    Tomiyama H; Miwa K; Shiga H; Moore YI; Oka S; Iwamoto A; Kaneko Y; Takiguchi M
    J Immunol; 1997 May; 158(10):5026-34. PubMed ID: 9144523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recognition of two overlapping CTL epitopes in HIV-1 p17 by CTL from a long-term nonprogressing HIV-1-infected individual.
    Harrer T; Harrer E; Barbosa P; Kaufmann F; Wagner R; Brüggemann S; Kalden JR; Feinberg M; Johnson RP; Buchbinder S; Walker BD
    J Immunol; 1998 Nov; 161(9):4875-81. PubMed ID: 9794421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice.
    Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Xiang J
    Vaccine; 2012 May; 30(24):3519-25. PubMed ID: 22484292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of HTLV-1-specific CTL directed against synthetic and naturally processed peptides in HLA-B*3501 transgenic mice.
    Schönbach C; Nokihara K; Bangham CR; Kariyone A; Karaki S; Shida H; Takatsu K; Egawa K; Wiesmüller KH; Takiguchi M
    Virology; 1996 Dec; 226(1):102-12. PubMed ID: 8941327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequence conservation of subdominant HLA-A2-binding CTL epitopes in HIV-1 clinical isolates and CD8+ T-lymphocyte cross-recognition may explain the immune reaction in infected individuals.
    Thorn M; Tang S; Therrien D; Kløverpris H; Vinner L; Kronborg G; Gerstoft J; Corbet S; Fomsgaard A
    APMIS; 2007 Jun; 115(6):757-68. PubMed ID: 17550385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interdisciplinary analysis of HIV-specific CD8+ T cell responses against variant epitopes reveals restricted TCR promiscuity.
    Hoof I; Pérez CL; Buggert M; Gustafsson RK; Nielsen M; Lund O; Karlsson AC
    J Immunol; 2010 May; 184(9):5383-91. PubMed ID: 20363973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single specific amino acid residue in peptide antigens is sufficient to activate memory CTL: potential role of cross-reactive peptides in memory T cell maintenance.
    Reali E; Guerrini R; Marastoni M; Tomatis R; Masucci MG; Traniello S; Gavioli R
    J Immunol; 1999 Jan; 162(1):106-13. PubMed ID: 9886375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress toward an artificial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization.
    Berzofsky JA
    Biotechnol Ther; 1991; 2(1-2):123-35. PubMed ID: 1726961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements.
    Huarte E; Sarobe P; Lu J; Casares N; Lasarte JJ; Dotor J; Ruiz M; Prieto J; Celis E; Borrás-Cuesta F
    Clin Cancer Res; 2002 Jul; 8(7):2336-44. PubMed ID: 12114438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
    Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
    J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and characterization of highly immunogenic and broadly recognized mimics of the HIV-1 CTL epitope Gag77-85.
    Boggiano C; Moya R; Pinilla C; Bihl F; Brander C; Sidney J; Sette A; Blondelle SE
    Eur J Immunol; 2005 May; 35(5):1428-37. PubMed ID: 15789356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The majority of currently circulating human immunodeficiency virus type 1 clade B viruses fail to prime cytotoxic T-lymphocyte responses against an otherwise immunodominant HLA-A2-restricted epitope: implications for vaccine design.
    Altfeld M; Allen TM; Kalife ET; Frahm N; Addo MM; Mothe BR; Rathod A; Reyor LL; Harlow J; Yu XG; Perkins B; Robinson LK; Sidney J; Alter G; Lichterfeld M; Sette A; Rosenberg ES; Goulder PJ; Brander C; Walker BD
    J Virol; 2005 Apr; 79(8):5000-5. PubMed ID: 15795285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of a primary human cytotoxic T-lymphocyte response against a novel conserved epitope in a functional sequence of HIV-1 reverse transcriptase.
    van der Burg SH; Klein MR; van de Velde CJ; Kast WM; Miedema F; Melief CJ
    AIDS; 1995 Feb; 9(2):121-7. PubMed ID: 7536421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.